U.S. Markets closed
  • S&P Futures

    3,969.00
    +3.25 (+0.08%)
     
  • Dow Futures

    33,810.00
    +7.00 (+0.02%)
     
  • Nasdaq Futures

    11,664.00
    +18.50 (+0.16%)
     
  • Russell 2000 Futures

    1,820.40
    +0.70 (+0.04%)
     
  • Crude Oil

    72.03
    +0.57 (+0.80%)
     
  • Gold

    1,805.40
    +3.90 (+0.22%)
     
  • Silver

    23.40
    +0.15 (+0.66%)
     
  • EUR/USD

    1.0574
    +0.0015 (+0.1375%)
     
  • 10-Yr Bond

    3.4910
    +0.0830 (+2.44%)
     
  • Vix

    22.29
    -0.39 (-1.72%)
     
  • GBP/USD

    1.2256
    +0.0018 (+0.1458%)
     
  • USD/JPY

    136.2260
    -0.4040 (-0.2957%)
     
  • BTC-USD

    17,226.95
    +356.83 (+2.12%)
     
  • CMC Crypto 200

    406.11
    +11.42 (+2.89%)
     
  • FTSE 100

    7,472.17
    -17.02 (-0.23%)
     
  • Nikkei 225

    27,946.21
    +371.78 (+1.35%)
     

Charles River Labs Is Still Facing a Downward Current

Charles River Labs Is Still Facing a Downward Current

Charles River Laboratories is a pharmaceutical company that specializes in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services. The cutting-edge Massachusetts-based company has been upgraded to a fundamental "buy" recommendation by a sell-side firm with a $240 price target. In the daily bar chart of CRL, below, we can see that the shares have been in a steady downtrend the past 12 months.